1 September 2020 in Colloids and Surfaces B: Biointerfaces
Nanoparticles (NPs) of three poorly water-soluble BCS class II active pharmaceutical ingredients (APIs) (clozapine (CLO), curcumin (CUR) and carbamazepine (CBMZ) with zeta potentials -28.5 ± 2.5, -33 ± 1.5 and -13 ± 1.5 mV respectively) were produced, stabilized and isolated into the solid state with the help of Montmorillonite (MMT) clay carrier particles. The nanoparticles of clozapine (27 nm), curcumin (170 nm) and carbamazepine (30 nm) were produced and stabilized in suspension using a reverse antisolvent precipitation technique in the presence of 'as received' MMT carrier particles (∼30 μm) and/or MMT carrier particles whose surface had been slightly modified with a cationic protein, protamine sulphate salt (PA). The resulting nanoparticle carrier composites were isolated directly from suspension into a solid state form by simple filtration followed by air-drying. The API dissolution rates from these dried NP-carrier composites were comparable with those of the respective stabilized API nanoparticles in suspension up to maximum CLO, CUR and CBMZ loadings of 23%, 21.8% and 33.3% (w/w) respectively, although surface modification of the MMT carrier particles with PA was needed for the CLO and CUR NP-carrier composites in order to preserve the fast API nanosuspension-like dissolution rates at higher API loadings. For both of these APIs, the optimal loading of PA on MMT was around 4 mg/g, which likely helped to limit aggregation of the API nanoparticles at the higher API loadings. Interestingly, no MMT surface modification was needed to preserve fast API dissolution rates at higher API loadings in the case of the CBMZ NP-carrier composites. This discrimination among the three APIs for carrier particle surface modification was previously observed in reported studies by our group for three other APIs, namely valsartan, fenofibrate and dalcetrapib. When examined together, the data for all six APIs suggest a general trend whereby API nanoparticles with zeta potentials more positive than around -25 mV do not require carrier particle surface modification with PA in order to preserve their fast dissolution rates from NP-carrier composites at higher API loadings. Thus, this study offers a potentially effective means of transforming poorly water soluble BCS Class II APIs into fast dissolving solid dosage NP-carrier composites, whereby the surface properties of the carrier particle can be tuned with prior knowledge of the zeta potential of the API nanoparticles.
19 September 2018 in Crystal Growth & Design
12 December 2017 in Crystal Growth & Design
This study is based on the heterogeneous nucleation of active pharmaceutical ingredients (APIs) in the presence of various excipients widely used in the pharmaceutical industry. Carbamazepine (CBMZ) was successfully crystallized in the presence of the following heterosurfaces: α/β-lactose, β-d-mannitol, microcrystalline cellulose, and carboxymethyl cellulose. The successful crystallization of CBMZ FIII in the presence of all the excipients was confirmed by powder X-ray diffraction and scanning electron microscopy, while CBMZ crystals’ apposition was confirmed using in situ scanning electronic microscopy-Raman. A pronounced improvement in the dissolution of CBMZ FIII was observed when crystallized in the presence of excipients when compared with CBMZ FIII recrystallized using the same conditions in the absence of the excipients. The isolated solids could be simply tabletted by direct compression upon mixing with the desired amount of disintegrant and lubricant. Hence employing this process could potentially streamline the downstream process in pharmaceutical industries and also increase the throughput with reduced cost.
1 March 2019 in Colloids and Surfaces B: Biointerfaces
21 February 2018 in Crystal Growth & Design
15 June 2018 in CrystEngComm
A new methanol solvate of clozapine base (CPB) has been identified. It exhibits different molecular arrangements and bonding environments at low and room temperatures, while still maintaining the same PXRD pattern throughout. Slurry experiments confirmed this CPB–MeOH solvate to be the thermodynamically stable form in suspension relative to CPB. The CPB–MeOH solvate was further characterised using TGA, DSC and VT-PXRD, with VT-PXRD confirming its conversion to CPB upon desolvation via heating. As confirmed by PXRD, CPB–MeOH solvate was also crystallized heterogeneously from MeOH in the presence of dextran (DEX), chitosan (CHT) and microcrystalline cellulose (MCC), with a significant reduction in induction time observed in the presence of all three excipients: 28, 18 and 15-fold in the presence of DEX, CHT, and MCC respectively. The CPB–MeOH solvate crystals in the resultant composite solids were desolvated to CPB upon heating to 120 °C for 6 h, causing their plate-like habit to deform to one containing pores and ridges. The accompanying increase in crystal surface area led to a 3 to 5-fold increase in the extent of CPB's dissolution from these desolvated CPB–MeOH crystals after 5 minutes and also after 1 h relative to normal CPB crystals. Therefore, the potential may exist to enhance the dissolution rate of a poorly-soluble active pharmaceutical ingredient (API), thereby improving its bioavailability, by crystallizing it as a solvate in the presence of an excipient heterosurface and thereafter desolvating the API crystals in the composite solid at high temperature. By so doing, it may no longer be necessary to mill such API crystals during drug formulation.